Want FREE Templates on Strategy & Transformation? Download our FREE compilation of 50+ slides. This is an exclusive promotion being run on LinkedIn.






Marcus Insights
PMO Integration Strategies for Post-Merger Pharmaceutical Success


Need help finding what you need? Say hello to Marcus. Based on our proprietary MARC [?] technology, Marcus will search our vast database of management topics and best practice documents to identify the most relevant to your specific, unique business situation. This tool is still in beta. If you have any suggestions or questions, please let us know at support@flevy.com.

Role: Head of PMO
Industry: large pharmaceutical

Situation: PMO Transition and Integration Discussion Points. Introduction: Overview of the meeting's purpose, acknowledging the ongoing merger and the need for clarity regarding the PMO's role in the new organizational structure. 1. Welcome and Introduction – Why are we here? (Context) Ambiguity about the internal PMO as a business unit within CGM would benefit from clarification of sponsor's vision – How the PMO will transition from Pcon to internal business unit and how will that business unit be structured. How the PMO will fit into the new organisation post fusion, and at what level, integrated into the solution layer or established independently at CGM portfolio level. Aspects of strategic planning are integrated into governance at the solution layer, would it be best practice to assign responsibilities (Technical/Operational/Immediate/reactive/Agile) at solution later with (Strategic/proactive/overarching) with the PMO whilst both maintaining cohesion to provide a 360 degree approach. 2. Overview of the current state of the PMO. The current PMO framework within CGM is primarily designed to provide technical and operational support, aligning closely with the solution layer to address immediate to short-term needs. This approach, initially mandated to Pcon, aimed to establish essential functions and processes to facilitate the journey to CGM's launch phase, inadvertently sidelining a longer-term strategic perspective in the workflow. This intense focus on technical details, such as cross-art integration and end-to-end testing, often overshadows the broader strategic requirements necessary for sustained growth and adaptation. As the project lifecycle has progressed, the immediate requirements have also shifted to mid to long term strategic goals While the governance framework theoretically incorporates these broader strategic elements, in practice, there is a lack of implementation of these aspects, leading to an overemphasis on immediate needs driven by SAFe principles. This focus, while effective for initial launch requirements, limits the organization's ability to maintain a holistic view of its long-term objectives, risks and adapt to evolving market demands. To address this imbalance, it would be prudent to adopt a blended approach that not only preserves the current framework's emphasis on technical and operational efficiency but also expands its scope to include a more pronounced strategic dimension at the portfolio level. Developing the future PMO, assigning immediate scope to the solution layer, with short, min to long term under the PMO would allow both technical agility and strategic oversight to exist. This integrated strategy would ensure that CGM's project management methodology remains robust and responsive in the short term while also being equipped to navigate and shape the organization's long-term trajectory whilst minimizing risk. 4. Sponsors vision for the PMO, how will the PMO be positioned Post Fusion. (JB) I would ask that the vision of the PMO be clarified, to prompt discussion I have included two possible scenarios, these may or may not align with the PMO organizational mandate, which is still yet to be defined, however they will add context and a basis for discussion. 5. Possible scenarios. PMO Scenario 1: The PMO serves as a vital link, aligning the technical and operational activities with the strategic goals of the leadership team. This model supports comprehensive planning, governance, performance tracking, and detailed KPI reporting, providing a holistic view of the portfolio to enable informed decision-making. The PMO's role is to facilitate rather than dictate, ensuring project teams retain autonomy while being supported. Advantages: Ensures an independent and objective overview of the entire portfolio, including cross-ART integration and end-to-end testing and commercialization, facilitating a strategic approach. Balances the immediate/agile technical requirements handled by the solution layer with the short to long-term strategic oversight managed by the PMO, promoting a dual integrated operational model. Enhances oversight on RAIDs at a portfolio level, leading to more effective risk management. Disadvantages: Challenges in resource and budget allocation, along with the planning and implementation cycle. The PMO would have to be planned and resources for a phased implementation whilst supporting the current workflows that will transition from Pcon. The PMO must ensure that governance mechanisms do not impede team agility, requiring processes that align with rather than disrupt existing workflows. Transition Scenario: The transition involves a phased Pcon exit, allowing the PMO to incrementally build its capabilities. This includes prioritizing PMO initiatives and defining the collaborative roles between the PMO and Pcon, fostering the PMO's strategic development with the assistance of Pcon. Delivers an integrated portfolio perspective, blending strategic planning with agile execution. Promotes a balance between immediate deliverables and long-term strategic objectives. PMO Scenario 2: Complete integration of PMO functions into the solution layer, ensuring continuity and efficiency without significant organizational change. Transition Scenario: Hard exit of Pcon with all workflows handed over by 03/24 or retention to allow shared responsibilities to allow for the development of the PMO function.

Question to Marcus:


I need to be able to present current sittuation, transition of workflows and proposed PMO


Ask Marcus a Question

Based on your specific organizational details captured above, Marcus recommends the following areas for evaluation (in roughly decreasing priority). If you need any further clarification or details on the specific frameworks and concepts described below, please contact us: support@flevy.com.

Change Management

The pharmaceutical industry is facing unprecedented change, particularly in the context of mergers and acquisitions. For the PMO, leading through this change is crucial.

It’s about moving from a current state to a desired future state while minimizing productivity loss, resistance from employees, and potentially negative impacts on Customer Satisfaction. Successful Change Management requires a clear communication plan, stakeholder engagement, and mechanisms to address resistance. The PMO must act as a bridge between the strategic vision and the operational implementation, ensuring that all team members are aligned with the new direction. Additionally, integrating change management principles into the PMO’s practices can help in swiftly adapting to future changes, making the organization more resilient and Agile.

Learn more about Change Management Agile Customer Satisfaction

Strategic Planning

Strategic Planning within the PMO context in a large pharmaceutical company involves aligning project initiatives with the broader business objectives, especially during Post-merger Integration. It's about understanding the long-term vision and identifying how the PMO can contribute to achieving these goals.

Strategic planning should focus on enhancing innovation, streamlining operations, and improving time to market for new drugs and therapies. Incorporating Market Analysis, competitive intelligence, and regulatory considerations into the planning process will ensure that the PMO can anticipate changes and adapt strategies accordingly. This approach not only improves project outcomes but also ensures that the organization remains competitive and compliant in a fast-evolving industry.

Learn more about Strategic Planning Post-merger Integration Market Analysis

Risk Management

In the pharmaceutical sector, the stakes of project failures can be high, affecting patient safety, regulatory compliance, and the company's reputation. A robust Risk Management framework is essential for the PMO to identify, assess, and mitigate risks across projects.

This includes clinical trial risks, regulatory risks, Supply Chain disruptions, and intellectual property challenges. Proactive risk management supports decision-making and prioritization of resources, safeguarding the organization against potential crises. The PMO should champion a culture of risk awareness, encouraging open discussions about uncertainties and potential issues. Implementing technology and analytics can further enhance risk monitoring and response strategies.

Learn more about Risk Management Supply Chain

Project Management

Effective Project Management is pivotal to the success of pharmaceutical companies, where projects range from research and development to market launch of new drugs. The PMO must ensure that project management methodologies are adapted to the unique needs of the industry, including compliance with regulatory standards, management of clinical trials, and coordination of cross-functional teams.

Emphasizing agile methodologies can improve responsiveness to change, facilitate collaboration, and accelerate project delivery. The PMO should also focus on developing project management competencies within the team, providing training, and implementing Best Practices to elevate project execution capabilities.

Learn more about Project Management Best Practices

Business Process Improvement

Business Process Improvement (BPI) is crucial in a fast-paced pharmaceutical environment to enhance efficiency, reduce costs, and improve product quality. The PMO should take a leading role in identifying process inefficiencies, redundancies, or bottlenecks and implementing improvements.

This may involve adopting new technologies, streamlining workflows, or redefining roles and responsibilities. BPI initiatives should be aligned with the strategic goals of the organization, ensuring that process changes contribute to overall business objectives. Engaging stakeholders and fostering a culture of Continuous Improvement are key to sustaining the benefits of BPI efforts.

Learn more about Process Improvement Continuous Improvement Business Process Improvement

Post-merger Integration

Post-merger integration (PMI) is a critical phase for the PMO in a pharmaceutical company undergoing a merger or acquisition. The PMO plays a pivotal role in ensuring that the integration of processes, systems, and cultures is executed smoothly and efficiently.

This involves meticulously planning the integration of project portfolios, harmonizing methodologies, and ensuring continuity of key projects. The PMO must also address cultural integration, aligning different Organizational Cultures to prevent conflicts and ensure a unified workforce. Focusing on clear communication, setting common goals, and establishing a shared vision are essential for a successful PMI.

Learn more about Organizational Culture Post-merger Integration

Data & Analytics

The utilization of data and analytics within the PMO can significantly enhance decision-making, risk assessment, and project outcomes in the pharmaceutical industry. By leveraging Data Analytics, the PMO can gain insights into project performance, identify patterns, and predict potential issues before they escalate.

This includes analyzing clinical trial data, monitoring project timelines, and assessing resource utilization. Implementing advanced analytics and AI can further enhance forecasting, optimize operations, and drive innovation. The PMO should champion the adoption of data-driven approaches, ensuring the necessary tools and skills are in place to leverage data effectively.

Learn more about Data Analytics Data & Analytics

Operational Excellence

Operational Excellence is key to achieving high efficiency and productivity in the pharmaceutical industry. The PMO should champion initiatives aimed at optimizing operations, from research and development to manufacturing and distribution.

This includes implementing lean principles to reduce waste, improving Supply Chain Management, and enhancing Quality Control measures. Fostering a culture of excellence and continuous improvement can drive sustainable improvements and Competitive Advantage. The PMO plays a critical role in aligning operational initiatives with strategic objectives, ensuring that operational improvements contribute to the overall success of the organization.

Learn more about Operational Excellence Supply Chain Management Competitive Advantage Quality Control

Supply Chain Resilience

Building a resilient supply chain is increasingly important for pharmaceutical companies, given the complexities of global operations and the critical nature of products. The PMO should work closely with supply chain management to identify vulnerabilities, such as dependency on single-source suppliers or geopolitical risks, and develop strategies to mitigate these risks.

This may involve diversification of the supplier base, implementing robust contingency plans, and enhancing supply chain visibility. Strengthening Supply Chain Resilience not only ensures the uninterrupted supply of critical materials but also supports the organization's ability to adapt to changes and disruptions in the market.

Learn more about Supply Chain Resilience

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.


How did Marcus do? Let us know. This tool is still in beta. We would appreciate any feedback you could provide us: support@flevy.com.

If you have any other questions, you can ask Marcus again here.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Additional Marcus Insights